Publications

Background:
Immunotherapy has emerged as a promising intervention in metastatic or recurrent cervical cancer, but response rates have been modest, albeit with some durable responses. To date, immune profiling and pathway characterization via whole transcriptome sequencing (WTS) has been limited to sampled tumors from newly diagnosed, mostly early stage disease. In the current study, we sought to use WTS-based immune profiling to develop a more representative analysis of the cervical cancer population receiving immunotherapy.